Gensco Pharma® Acquires Global Rights and IP for RizaFilm® and RizaPort®
Gensco Pharma acquires global rights to RizaFilm® and RizaPort®, with a U.S. migraine treatment launch planned for Q4 2025 and global expansion ahead.
Rizaport
Gensco® Pharma Partners with IntelGenx to Launch and Commercialize RIZAFILM® (U.S. market name for RIZAPORT® — Rizatriptin Oral Film) in the United States
Miami, Florida, December 12, 2018 – Gensco® Pharma, a leading specialty pharmaceutical manufacturer specializing in development and commercialization of prescription transdermal products, today announced the execution of a definitive licensing, development and supply...LOOKING TO THE FUTURE
Launching in Q4 2025, RizaFilm® delivers fast, water-free migraine relief through novel oral dissolvable film (ODF) technology.